Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Amylase concentration linked to mortality in guinea pigs
Researchers say the digestive enzyme is often overlooked.
Guinea pigs with high plasma concentrations of amylase face increased mortality.

Researchers have revealed the clinical significance of plasma amylase to the lifespan of guinea pigs.

The new study has found that guinea pigs which recorded particularly high plasma concentrations of amylase were more likely to die within 30 days of biochemistry analysis.

To investigate the causes of mortality in guinea pigs, researchers retrospectively analysed the medical records of 278 guinea pigs treated in four different institutions. The guinea pigs had all undergone a biochemistry panel, had their plasma concentrations measured and had a follow-up 30 days later.

The guinea pigs had been brought to the institutions for a number of reasons, including emergencies, sickness and wellness appointments. Among their diagnoses were integument disease, reproductive issues and gastrointestinal disease.

Using this data, the research team analysed the guinea pigs’ survival rates and drew comparisons to their amylase concentrations.

The analysis revealed that guinea pigs which recorded an elevated level of plasma amylase concentration (1910 to 3985 U/L) were seven times more likely to die in the next 30 days than those with a concentration within the reference intervals (1339 to 1573 U/L).

It also found increased mortality risk among guinea pigs with high blood urea nitrogen (BUN) concentrations. Guinea pigs with BUN concentrations higher 62 mg/dL had a 30 times increase in their mortality risk.

Ashley Souza and Sarah Ozawa, lead authors of the study, said: “Guinea pigs can be a challenging species to treat, especially when they enter a veterinary hospital in critical condition.

“It is our hope that this study provides further diagnostic tools for veterinarians to use when explaining options and prognosis to an owner, helping guide treatment and care for this species.”

Amylase is a digestive enzyme, which researchers say is often overlooked. Its clinical significance is largely misunderstood, however researchers now say that high amylase levels could indicate a sick guinea pig requires more diagnostic testing or supportive care.

The researchers say that, because the prognostic capacity of amylase is limited, the amylase concentration data should only be used as part of the bigger clinical picture and should not solely inform veterinary decisions.

The full study can be found in the Journal of Small Animal Practice.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.